The Global HIV Vaccine Enterprise enables greater collaboration among organizations involved in HIV vaccine research and development by promoting more efficient, faster ways for researchers to share successes and failures and avoid duplication of efforts. The Enterprise calls for complementing current investigator-led efforts with large-scale, well-funded, collaborative efforts across institutions and disciplines, and tackling major scientific problems that have proven too difficult for any one group to tackle alone. In addition, Enterprise stakeholders are also exploring a variety of new approaches to encourage innovation and support high-risk/high-reward ideas to HIV vaccine discovery efforts.
The Enterprise is comprised of organizations and individuals working together to implement a shared Scientific Strategic Plan. These include funding agencies, research organizations, non-government organizations, international agencies, and individual scientists supported by different programs that have been launched or realigned to target the Scientific Strategic Plan research priorities.
Enterprise Stakeholders Include:
|
|
